Primaxin
(Imipenem)Phase 3Small molecule
PfizerImipenem is an antibiotic used to treat serious bacterial infections in the hospital setting, including infections of the blood, lungs, abdomen, and urinary tract.[1] Primaxin is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Primaxin is one of 151 small molecule programs targeting Bacterial Disease. It is currently in Phase 3.
7
Indications
19
Total Trials
1
Active Trials
150
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
112 competitors in Sepsis
#DrugCompanyPhaseTrials
1Primaxin
PfizerPhase 3
Dobutrex
Eli LillyPhase 2
Proamatine
TakedaPhase 2
Gleevec
NovartisPhase 2
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 2
Nafamostat Mesylate
EEnsysce Biosciences
Phase 3
Hydrocortisone Administration
UUniversity of Virginia
Phase 3
AZD4144
AstraZenecaPhase 2
Simdax
Orion Corporation, Orion PharmaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neutropenia2 trials
Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia
Completed·—·N/A·NCT01714570·123 enrolled
Pneumonia2 trials
11 more indications
Bacterial Pneumonia1 trial
Hematological Malignancies1 trial
Cirrhosis1 trial
Urinary Tract Infection1 trial
Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli
Terminated·—·Phase 4·NCT02474706·6 enrolled
Ventilator-Associated Pneumonia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Imipenem. EMBL-EBI & Wellcome Sanger Institute.
- [4]